What to Know About Blood Clots, Anaphylaxis and Other Vaccine Fears
Covid vaccines are designed to prevent a disease that has so far killed nearly 3 million worldwide. No pharmaceutical, however, is completely benign. The goal is to ensure the benefits outweigh the risks. So far, the vaccines have been connected to a relatively small number of cases of blood clots and serious, but treatable allergic reactions called anaphylaxis. Other concerns -- about vaccinations causing temporary facial paralysis, heart inflammation and otherwise unexplained deaths -- have eiwashingtonpost.com
Fauci tells graduates 'virus is the enemy, not each other;' Sanofi and GSK vaccine reports mid-stage immune response. Live COVID-19 updates
The return of in-person graduations across the country, Sanofi and GSK rejoin the COVID-19 vaccine effort and more COVID updates to start your Monday.usatoday.com
Sanofi to help second rival produce COVID-19 vaccines
FILE - In this Feb. 7, 2019 the logo of French drug maker Sanofi is pictured at the company's headquarters, in Paris. Sanofi is going to produce as many as 12 million coronavirus vaccine doses per month for rival Johnson & Johnson, the second time the French drug maker is turning over production facilities to speed up supplies of a rival company's vaccine, while its own candidate faces delays. The French plant is expected to produce about 12 million doses per month, starting in the second half of this year. Sanofi had already previously announced that its facilities in Frankfurt, Germany, also will help bottle and package 125 million vaccine doses for the rival partnership of Pfizer-BioNTech. His government has pressed Sanofi to use its facilities to help make vaccines from its rivals, because of the high global demand for vaccines and supply problems.
The Latest: Mexico receives shipment of Sputnik V vaccine
A medical worker prepares a shot of Russia's Sputnik V coronavirus vaccine in a local rural medical post in the village of Ikhala in Russias Karelia region, Tuesday, Feb. 16, 2021. (AP Photo/Dmitri Lovetsky)MEXICO CITY — Mexico has received its first shipment of Russia’s Sputnik V COVID-19 vaccine. Mexico received its first shipment of vaccines from Pfizer in mid-December, but turned to Sputnik V in January when other expected vaccine shipments were delayed. The company reiterated that it will have capacity to provide 100 million vaccine doses to the U.S. by the end of June. ___WASHINGTON — The White House now says it expects to catch up by mid-week on deliveries of coronavirus vaccine doses that were delayed by severe weather.
EXPLAINER: Why it's hard to make vaccines and boost supplies
FILE - In this Friday, Jan. 22, 2021 file photo, empty vials of the Pfizer-BioNTech COVID-19 vaccine are seen at a vaccination center at the University of Nevada, Las Vegas in Las Vegas. (AP Photo/John Locher)With demand for COVID-19 vaccines outpacing the world’s supplies, a frustrated public and policymakers want to know: How can we get more? Makers of COVID-19 vaccines need everything to go right as they scale up production to hundreds of millions of doses — and any little hiccup could cause a delay. “It’s just not that easy.”DIFFERENT VACCINES, DIFFERENT RECIPESThe multiple types of COVID-19 vaccines being used in different countries all train the body to recognize the new coronavirus, mostly the spike protein that coats it. But possibly the easiest way to get more doses is if other vaccines in the pipeline are proven to work.
The Latest: More rules for returning New Zealand travelers
(Peter Meecham/New Zealand Herald via AP)WELLINGTON, New Zealand — Travelers returning to New Zealand will face stricter rules at quarantine hotels as health authorities investigate how up to three people got infected with the coronavirus while isolating at Auckland’s Pullman Hotel. The record increase of 65 deaths is three more than the previous one-day record reported on Jan. 6, according to health department records. The university and county health department are asking students to limit leaving their residence to going to classes, getting food, work and other necessary in-person activities. The health department said in the news release that if the case counts continues to rise, stricter measures will have to be applied. The previous one-day record of 62 was reported Jan. 6, according to the Oklahoma State Department of Health.
France's Sanofi to help rival Pfizer-BioNTech make vaccines
French drug maker Sanofi said Wednesday it will help manufacture 125 million doses of the coronavirus vaccine developed by rivals Pfizer and BioNTech, while its own vaccine candidate faces delays. Sanofi's Frankfurt facilities will help with late-stage production of vaccines prepared by Germany-based BioNTech, including bottling and packaging, starting in the summer, according to a Sanofi official. The French government has pressed Sanofi to use its facilities to help make vaccines from its rivals, given the high demand and supply problems. Sanofi is still pushing ahead with its own COVID-19 vaccine efforts, including a much-awaited candidate developed with British partner GlaxoSmithKline. The multiple types of COVID-19 vaccines being used in different countries require different technologies, raw materials, equipment and expertise.
One health-care stock looks like a buy as Pfizer begins Covid vaccine rollout, market analyst says
Health-care stocks are in focus after Pfizer began shipments in the U.S. of its Covid vaccine and the first vaccinations were given this week. It's not just the companies developing and delivering Covid vaccines that have caught one market analyst's eye. Boris Schlossberg, managing director of FX strategy at BK Asset Management, said French pharmaceutical company Sanofi could be worth a second look. As investors wait for those tail winds to give the stock a lift, Schlossberg said its current fundamentals and pipeline also make Sanofi a solid health-care play. Ari Wald, head of technical analysis at Oppenheimer, is betting on one group of health-care stocks rather than the entire sector.cnbc.com
GSK, Sanofi say COVID-19 vaccine won't be ready until late 2021
Drugmakers GlaxoSmithKline and Sanofi say their potential COVID-19 vaccine won't be ready until late next year as they seek to improve the shot's effectiveness in older people. They said they now expect the vaccine to be available in the fourth quarter of 2021. GSK and Sanofi, based in London and Paris, respectively, said they were confident of the vaccine's ultimate success due to positive results from other tests. In adults ages 18 to 49, the vaccine produced an immune response comparable to patients who had recovered from COVID-19, the companies said. Separately, Pfizer's COVID-19 vaccine is likely to soon receive emergency use authorization from the Food and Drug Administration after a federal advisory panel on Thursday recommended the step.cbsnews.com
Sanofi, GSK say COVID-19 shot won't be ready until late 2021
LONDON – Drugmakers Sanofi and GlaxoSmithKline said Friday that their potential COVID-19 vaccine won’t be ready until late next year because they need to improve the shot’s effectiveness in older people. “The results of the study are not as we hoped,’’ Roger Connor, president of London-based GSK Vaccines, said in a statement. GSK and Sanofi plan to produce up to 1 billion doses of their COVID-19 vaccine annually, and they have signed agreements to supply millions of doses to the U.S., European Union, Canada and developing countries. The difficulties underscore the challenges scientists face as they race to develop COVID-19 vaccines, condensing a process that usually takes years into a matter of months. “We have identified the path forward and remain confident and committed to bringing a safe and efficacious COVID-19 vaccine,” said Thomas Triomphe, head of Sanofi’s vaccine unit.
Sanofi, GSK to provide 200 million Covid vaccine doses to WHO global immunization program
The deal is contingent on the vaccine winning regulatory approval, the companies said in a statement. "Since we started working on the development of COVID-19 vaccines, GSK has pledged to make them available to people around the world," Roger Connor, president of GSK Vaccines, said in a statement. He added that "this has the potential to be a significant contribution to the global fight against COVID-19." The WHO has previously acknowledged that there won't be enough vaccine doses for everyone in the world once one candidate is authorized for use. "The more shots on goal we have, the higher the chances of having a very safe, very efficacious vaccine."cnbc.com
Sanofi isn't cutting corners in coronavirus vaccine development despite acceleration, CEO says
Sanofi CEO Paul Hudson told CNBC on Thursday that the pharmaceutical company is not cutting any corners in its pursuit of developing a coronavirus vaccine. Sanofi, which is headquartered in Paris, France, is developing two potential vaccines to prevent the coronavirus. One of the vaccines is being developed alongside British firm GlaxoSmithKline and began early clinical trials on Sept. 3. Sanofi also is partnering with Massachusetts-based Translate Bio on a separate vaccine, with the aim of beginning human trials in November. Hudson's comments come amid concern over whether the typical, years-long scientific process for vaccine development is being jeopardized for the sake of speed during the Covid-19 pandemic.cnbc.com
The Latest: $14M more in virus funds for 3 Ariz universities
Nearly 25% of the cases reported Thursday were in Multnomah County, Oregon’s most populous county and home to Portland. Missouri is dealing with a surge in new coronavirus cases, with 1,580 more confirmed cases reported Wednesday. State officials reported 333 new confirmed cases of the respiratory virus on Thursday, topping the previous single-day record set less than a week ago. The state Department of Health Services reported 566 new confirmed cases across the state, bringing the confirmed total to 215,852. The state reported 565 people hospitalized on Wednesday, down from the mid-July high of more than 3,500.
Stocks making the biggest moves in the premarket: Tractor Supply, Disney, Boeing, Tesla & more
Tractor Supply shares are up 47% since nationwide lockdowns began in mid-March, the best gain of any retail stock in the S&P 500. Walt Disney (DIS) Disney will submit a plan today to Orange County officials for reopening its Walt Disney World resort. Disney needs approval from the county and then from the governor before Walt Disney World can reopen. Amazon.com (AMZN) Amazon is in advanced talks to buy Zoox, according to The Wall Street Journal. Comparable-store sales in the U.S. increased by 14% between March 23 and May 17, but international sales were up by just 1% during that same period.cnbc.com
5 things to know before the stock market opens Monday
Regeneron, Sanofi say arthritis drug promising on sickest Covid-19 patientsRegeneron and Sanofi's rheumatoid arthritis drug showed promise for treating the sickest Covid-19 patients in a clinical trial. However, the companies stopped testing Kevzara on patients with less-advanced disease because it was not being shown as beneficial. As the world remains anxious for a treatment for Covid-19, confusion emerged last week over the possible effectiveness of Gilead Sciences' antiviral drug remdesivir. Gilead took issue with a draft document accidentally published by the World Health Organization that showed disappointing results from a remdesivir clinical trial in China. Earlier this month, health publication STAT News reported that Covid-19 patients in Chicago taking remdesivir as part of another clinical trial were recovering rapidly.cnbc.com
Stocks making the biggest moves in the premarket: American Express, Verizon, Intel, Tesla & more
Verizon (VZ) Verizon beat consensus estimates by 3 cents a share, with quarterly earnings of $1.26 per share. Revenue was below Wall Street forecasts, however, and the company cut its full-year outlook. Intel (INTC) Intel reported quarterly profit of $1.45 per share, beating the consensus estimate of $1.28, with the chip maker's revenue also beating Wall Street forecasts. J.C. Penney (JCP) J.C. Penney is in advanced bankruptcy talks with lenders, according to The Wall Street Journal. The medical products maker's revenue also topped Wall Street forecasts.cnbc.com
If Sanofi's coronavirus vaccine works, CEO says it can produce up to 600 million doses next year
French drugmaker Sanofi expects to produce up to 600 million doses of its coronavirus vaccine next year if its clinical trials with GSK go as planned, CEO Paul Hudson said Friday. Sanofi and GSK announced Tuesday that they entered an agreement to jointly create a Covid-19 vaccine by the end of next year. There are currently no therapies to treat Covid-19 and drugmakers are racing to produce a vaccine, which is expected to take 12 to 18 months. Johnson & Johnson said it is aiming to produce between 600 million and 900 million doses of its potential coronavirus vaccine by the end of the first quarter of 2021 if human trials scheduled to begin in September go as planned. The drug is in clinical trials examining its effectiveness in treating the coronavirus, but it is not a proven treatment yet.cnbc.com
Coronavirus live updates: California governor outlines guide to reopening state, US airports see $10 billion in aid
Maggie Fitzgerald6:16 pm: March retail sales will look horrible after the coronavirus pandemic forced consumers to stay homeWhen the economy shut down, consumers also shut down. Many have lost their jobs with 17 million workers filing for unemployment over the three weeks ending April 4. Many businesses have sent employees home or furloughed them amid shutdowns tied to the coronavirus pandemic. Berkeley Lovelace Jr.12:09 pm: New York coronavirus deaths are leveling off, but at a 'devastating level of pain and grief,' Gov. The social and economic restrictions, which range from school closures to social distancing and bans on public gatherings, were brought in to try to slow the spread of the coronavirus pandemic.cnbc.com
GlaxoSmithKline CEO calls coronavirus vaccine partnership with Sanofi an 'unprecedented collaboration'
GlaxoSmithKline CEO Emma Walmsley on Tuesday told CNBC's Jim Cramer that her company's newly announced partnership with industry peer Sanofi is an "unprecedented collaboration" between competitors. The European pharmaceutical giants are combining their resources to develop a Covid-19 vaccine and aim to produce a batch within the next 20 months. "But, a lot of work to do, and we're sure the world will need more than one vaccine, considering the state of demand." The two companies are "leaders who are both bringing proven pandemic technologies and scale to develop, hopefully, an adjutant vaccine against Covid-19," Walmsley said. "As the world faces this unprecedented global health crisis, it is clear that no one company can go it alone," Sanofi CEO Paul Hudson said in a statement.cnbc.com
Sanofi partners with GSK for developing coronavirus vaccine
Sanofi and GSK have entered an agreement to jointly create a Covid-19 vaccine by the end of next year. Andrew Cuomo said Monday the coronavirus crisis will end only when an effective vaccine is developed and made widely available. Inovio Pharmaceuticals pushed out phase 1 of clinical human testing this week, making it the second potential Covid-19 vaccine to undergo human testing. The first human trial for a vaccine started in March, and was developed by Moderna and the federal National Institutes of Health. Sanofi said it will use its genetics technology and antigen and GSK will contribute its unproven pandemic technology, which theoretically includes the ability to measure dosage and effectiveness.cnbc.com
Stocks making the biggest moves in the premarket: J&J, Sanofi, Regeneron, La-Z-Boy, Apple & more
Sanofi (SNY), Regeneron Pharmaceuticals (REGN) The drugmakers expanded a clinical trial of their rheumatoid arthritis drug Kevzara as a coronavirus treatment. United Technologies will be renamed Raytheon Technologies and trade under the ticker "RTX." The Carrier and Otis businesses of United Technologies will become separate publicly traded companies, trading under ticker symbols "CARR" and "OTIS," respectively. La-Z-Boy (LZB) La-Z-Boy furloughed 6,800 workers, cut the pay of senior management by 50%, and of salaried workers by 25%. Gilead Sciences (GILD) Gilead said it would stop taking individual emergency requests for its experimental coronavirus drug due to overwhelming demand.cnbc.com
Sanofi, Regeneron expand testing of potential coronavirus treatment
The logo of Sanofi is seen at the company's research and production centre in Vitry-sur-Seine, France, August 6, 2019. Sanofi and Regeneron Pharmaceuticals Inc have expanded a clinical trial of their rheumatoid arthritis drug Kevzara as a coronavirus treatment to patients outside the United States. The new coronavirus, called SARS-CoV2, has now infected more than 700,000 people worldwide, and over 30,000 people have died from it, according to a Reuters tally. The United States has the most reported cases of any country in the world, with more than 130,000 cases of COVID-19. Regeneron is leading the U.S. trials, while Sanofi is leading trials outside the U.S.cnbc.com
Hopes are high for a coronavirus treatment, which could come much quicker than a vaccine
Moderna has developed the first experimental coronavirus medicine, but an approved treatment is more than a year away. David L. Ryan | Boston Globe | Getty ImagesScientists around the globe are racing to develop tests, treatments and vaccines to combat the COVID-19 disease. Health-care experts broadly agree that a treatment is likely to come before a vaccine. "If a good treatment emerges, whatever it is, we expect regulators to prioritize expeditious review," Laura Sutcliffe, a UBS health-care analyst said in a research note. Chloroquine is a generic malaria drug which has shown promise as a treatment against COVID-19.cnbc.com
Coronavirus highlights the $35 billion vaccine market. Here are the key players
The coronavirus outbreak is bringing attention to the fast-growing vaccine industry. The vaccine market has grown sixfold over the past two decades, worth more than $35 billion today, according to AB Bernstein. These companies have jumped into the race to combat the deadly coronavirus, working on vaccine or drug programs. Experts have warned despite recent advances, the public shouldn't expect a coronavirus vaccine to hit the market until early next year. The Bernstein analyst said Sanofi and GlaxoSmithKline both have a stable vaccine portfolio, including shingles, flu, pertussis and polio vaccines, that will keep driving revenue.cnbc.com
Stocks making the biggest moves premarket: Clorox, McKesson, Sirius XM, Alphabet & more
Revenue also topped estimates and Clorox raised its full-year outlook as cost savings and price increases made up for increased costs. McKesson (MCK) The drug distributor earned an adjusted $3.81 per share for its latest quarter, beating the $3.56 a share consensus estimate. Sirius XM (SIRI) The satellite radio operator matched forecasts with quarterly earnings of 5 cents per share, while revenue beat estimates. Alphabet (GOOGL) The Google parent reported quarterly earnings of $15.35 per share, well above the $12.53 a share consensus estimate. Cummins (CMI) The engine maker reported quarterly profit of $2.56 per share, 14 cents a share above estimates.cnbc.com
Sanofi issues voluntary recall of Zantac OTC medication
Drew Angerer/Getty Images(CNN) - Sanofi says it's voluntarily recalling its over-the-counter heartburn drug Zantac in the U.S. and Canada because of concerns of potential cancer risks. The FDA has said that some ranitidine medications -- including those known by the brand name Zantac -- contain low levels of an impurity that could cause cancer. Numerous recalls have been launched as the FDA found "unacceptable levels" of nitrosamines in several of those common drugs containing valsartan. Yet that study also noted that research into long-term cancer risk is needed. "Sanofi encourages anyone using Zantac OTC to speak with their health care providers or pharmacists if they have any additional questions," the company's statement said.
Shipments of generic Zantac halted amid cancer concerns
Drew Angerer/Getty Images(CNN) - Drugmaker Novartis said it is halting distribution of all ranitidine medicines made by Sandoz, a measure it called "precautionary" after the acid-reducing medications were found to contain an impurity. The FDA is evaluating whether the low levels of NDMA in ranitidine pose a risk to patients and said it will share the information when it is available. In case of concerns, adequate additional measures will be implemented in alignment with relevant Health Authorities as required," Novartis said in an emailed statement. "The FDA reported that the levels of N-nitrosodimethylamine (NDMA) in ranitidine in preliminary tests barely exceed amounts found in common foods. The FDA has been investigating NDMA and other impurities in blood pressure and heart medicines known as ARBs since last year.
Eli Lilly confirms probe by New York's Attorney General over insulin prices
A box of Eli Lilly & Co. Humalog brand insulin delivery devices are arranged for a photograph at a pharmacy in Princeton, Illinois. Attorney general offices in Mississippi, Washington D.C., California, Florida, Hawaii, and Nevada are also seeking information on its pricing, Eli Lilly said in the filing. It also received a civil investigative demands from attorney general offices in Washington and New Mexico. Eli Lilly did not respond to requests for comment. Earlier this week, drugmaker Sanofi disclosed that it, Eli Lilly and Novo Nordisk had received subpoena from New York's AG.cnbc.com
Stocks making the biggest moves premarket: Pfizer, Mylan, BlackRock, Blackstone, Domino's & more
Separately, Pfizer reported adjusted quarterly profit of 80 cents per share, 5 cents a share above estimates. Mylan reported adjusted quarterly profit of $1.03 per share, beating consensus by 8 cents a share. Genomic Health Genomic Health agreed to be bought by cancer diagnostics company Exact Sciences for $2.8 billion in cash and stock. Exact Sciences also issued its quarterly numbers this morning, losing 30 cents per share compared to a consensus estimate of a 56 cent loss. Blackstone London Stock Exchange is in advanced talks to buy financial data provider Refinitiv majority owned by Blackstone for $27 billion including assumed debt.cnbc.com